Sugi Predict

Sugi Predict / Compounds / SCHEMBL17560433

SCHEMBL17560433

SCHEMBL17560433

CC(C)(C)OC(=O)N1CCNCC1C(N)=O

nearest known ligand 0.45

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.40
▸ MC4R P32245 1/20 0.36
▸ MC5R P33032 1/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ USP2 O75604 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ NR1H2 P55055 1/20 0.35
▸ LMNA P02545 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8554343 1.00 PARP1 (0.43) PARP1HSD17B10MC4RMC5RSMN1; SMN2
SCHEMBL8554593 1.00 PARP1 (0.43) PARP1HSD17B10MC4RMC5RSMN1; SMN2
SCHEMBL2827159 0.88 PARP1 (0.42) PARP1HSD17B10MC4RMC5RSMN1; SMN2
SCHEMBL28704904 0.86 PARP1 (0.44) PARP1HSD17B10MC4RMC5RSMN1; SMN2
SCHEMBL18673224 0.86 PARP1 (0.44) PARP1HSD17B10MC4RMC5RSMN1; SMN2
SCHEMBL7995550 0.86 PARP1 (0.44) PARP1HSD17B10MC4RMC5RSMN1; SMN2
SCHEMBL1685922 0.86 HSD17B10 (0.47) PARP1HSD17B10MC4RMC5RSMN1; SMN2
SCHEMBL2480988 0.86 HSD17B10 (0.47) PARP1HSD17B10MC4RMC5RSMN1; SMN2
SCHEMBL2480835 0.86 HSD17B10 (0.47) PARP1HSD17B10MC4RMC5RSMN1; SMN2
SCHEMBL2584375 0.86 PARP1 (0.44) PARP1HSD17B10MC4RMC5RSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114746419-B N- (3- (5- (pyrimidin-4-yl) thiazol-4-yl) phenyl) sulfonamide compounds and their use as BRAF inhibitors 国家医疗保健研究所 2023-10-24 — — CN disclosed
EP-3654968-B1 METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF MERCK SHARP & DOHME LLC (US) 2023-08-16 — — EP disclosed
EP-3654968-B1 METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF MERCK SHARP & DOHME LLC (US) 2023-08-16 — — EP disclosed
US-20230036867-A1 N-(3-(5-(PYRIMIDIN-4-YL)THIAZOL-4-YL)PHENYL)SULFONAMIDE COMPOUNDS AND THEIR USES AS BRAF INHIBITORS INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2023-02-02 — — US disclosed
EP-4069692-A1 N-(3-(5-(PYRIMIDIN-4-YL)THIAZOL-4-YL)PHENYL)SULFONAMIDE COMPOUNDS AND THEIR USES AS BRAF INHIBITORS Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2022-10-12 — — EP disclosed
CN-114746419-A N- (3- (5- (pyrimidin-4-yl) thiazol-4-yl) phenyl) sulfonamide compounds and their use as BRAF inhibitors 国家医疗保健研究所 2022-07-12 — — CN disclosed
CN-114213415-A Macrocyclic pyrimidine derivatives 詹森药业有限公司 2022-03-22 — — CN disclosed
US-11207312-B2 Metallo-beta-lactamase inhibitors and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2021-12-28 — — US disclosed
WO-2021110997-A1 N-(3-(5-(PYRIMIDIN-4-YL)THIAZOL-4-YL)PHENYL)SULFONAMIDE COMPOUNDS AND THEIR USES AS BRAF INHIBITORS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2021-06-10 — — WO disclosed
US-20200281913-A1 Metallo-Beta-Lactamase Inhibitors and Methods of Use Thereof MERCK SHARP & DOHME CORP. (US) 2020-09-10 — — US disclosed
EP-3654968-A1 METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF Merck Sharp & Dohme Corp. (US) 2020-05-27 — — EP disclosed
EP-3055290-B1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2019-10-02 — — EP disclosed
US-20190071416-A1 COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2019-03-07 — — US disclosed
WO-2019018186-A1 METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF MERCK SHARP & DOHME CORP. (US) 2019-01-24 — — WO disclosed
CN-108480890-A One kind being used for underground engineering waste pipe welder and its working method 徐州工程学院 2018-09-04 — — CN disclosed
WO-2016034134-A1 HETEROAROMATIC DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2016-03-10 — — WO disclosed
CN-102770429-A Substituted aminothiazolone indazoles as estrogen related receptor-alpha modulators JANSSEN PHARMACEUTICA NV 2012-11-07 — — CN disclosed
CN-101102818-A Medicaments comprising carbonyl compounds, and the use thereof MERCK PATENT GMBH (DE) 2008-01-09 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190071416-A1 COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS SMYD3, SMYD2, EHMT1 PARP1 615/4885HSD17B10 2834/4885MC4R 2248/4885
US-20230036867-A1 N-(3-(5-(PYRIMIDIN-4-YL)THIAZOL-4-YL)PHENYL)SULFONAMIDE COMPOUNDS AND THEIR USES AS BRAF INHIBITORS BRAF, RAF1, NRAS PARP1 2767/4885HSD17B10 4556/4885MC4R 2821/4885
US-20200281913-A1 Metallo-Beta-Lactamase Inhibitors and Methods of Use Thereof MLX, MMP12, SLC11A2 PARP1 2078/4885HSD17B10 805/4885MC4R 4742/4885
US-11207312-B2 Metallo-beta-lactamase inhibitors and methods of use thereof MLX, MMP12, SLC11A2 PARP1 2078/4885HSD17B10 805/4885MC4R 4742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.